Clinical observation on gemcitabine associated with navelbine in the treatment of 23 cases with advanced non-small cell lung cancer resistant to platinum

Objective: To value the the efficacy and toxicities of gemcitabine(GEM) associated with navelbine(NVB) (GN protocol) on treatment of patients with advanced non-small cell lung cancer(NSCLC) resistant to platinum.Methods: Twenty-three cases of NSCLC anciently treated with platinum for two cycles with no obvious therapeutic effect were treated with GN.The details on the therapy are as follows:GEM was taken through the intravenous dripping at 1 000 mg/m² on the day 1st and day 8th while NVB was taken through the intravenous dripping at 25 mg/m² on the day 1st and day 8th.Results: These patients who were treated with GN were acquired 39.1% of the total effective rate,9.8 months of the median survival time,5.7 months of the illness advancing time and 45.8% of one-year survival rate.The major toxicity lies with the hematology,it is manifested by 78.3% of the decrease on the white cellⅠ~Ⅱ,13.0% of the decrease on the white cell Ⅲ~Ⅳ,43.5% of theⅠ~Ⅱ decrease on the platelet and 30.4% of anemia.The toxicity in the non-hematology includes vomiting,nausea and local phlebitis and so on.Conclusions: GN protocol with GEM associated with NVB has a superior therapeutic effect on advanced NSCLC resistant to Platinum with endurable side effects,which is worth popularizing and applying in the clinic.